Eflornithine for treatment of high-risk neuroblastoma
Trends in Pharmacological Sciences · 2024-06 · 45 (6) · 577-578
DOI: 10.1016/j.tips.2024.04.005 ↗Kurz gefasst
Leserbrief in der Zeitschrift Trends in Pharmacological Sciences, 2024-06. Verfasst von Jianxiong Jiang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Department of Anatomy and Neurobiology, Drug Discovery Center, Neuroscience Institute, The University of Tenne…. Hauptthemen laut MEDLINE: Neuroblastoma, Eflornithine. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, National Institutes of Health, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Department of Anatomy and Neurobiology, Drug Discovery Center, Neuroscience Institute, The University of Tennessee Health Science Center, Memphis, TN 38163, USA. Electronic address…
Förderung
- NINDS NIH HHS
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Jiang, J., & Yu, Y. (2024). Eflornithine for treatment of high-risk neuroblastoma. Trends in Pharmacological Sciences, 45(6), 577-578. https://doi.org/10.1016/j.tips.2024.04.005
Vancouver
Jiang J, Yu Y. Eflornithine for treatment of high-risk neuroblastoma. Trends in Pharmacological Sciences. 2024;45(6):577-578. doi:10.1016/j.tips.2024.04.005
BibTeX
@article{Jiang2024,
author = {Jiang, Jianxiong and Yu, Ying},
title = {Eflornithine for treatment of high-risk neuroblastoma},
journal = {Trends in Pharmacological Sciences},
year = {2024},
volume = {45},
number = {6},
pages = {577--578},
doi = {10.1016/j.tips.2024.04.005}
}
EUVIMED